Suppressive activity rather than frequency of FoxP3+ regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment

Human Immunology

Volumn 71, Issue 1, 2010, Pages 36-44

  Reinartz, Silke ^a   Pfisterer, Jacobus ^b   du Bois, Andreas ^c   Jackisch, Christian ^d   Baumann, Klaus H ^a   Wagner, Uwe ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Ubbo Emmius Klinik gGmbH   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d Klinikum Offenbach GmbH   (Germany)

Author keywords

Abagovomab; Antiidiotype; Clinical trials; Ovarian cancer; Regulatory T cells

Indexed keywords

ABAGOVOMAB; CA 125 ANTIGEN; CANCER VACCINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; OVARY CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 71449100966     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.09.356     Document Type: Article

References (34)

1. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol 38 (2008) 901-937
2. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
3. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
4. - T regulatory cells on the generation of cytotoxic T-cell response to a self but human tumor-associated epitope in vitro. J Immunol 176 (2006) 984-990
5. + T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 98 (2006) 17-29
6. Ichihara F., Kono K., Takahashi A., Kawaida H., Hidemitsu S., and Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9 (2003) 4404-4408
7. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9 (2003) 606-612
8. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 (2006) 7398-7405
9. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumor from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61 (2001) 4766-4772
10. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
11. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
12. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11 (2005) 8326-8331
13. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 125 (1974) 373-389
14. Coutinho A. Will the idiotypic network help to solve natural tolerance?. Trends Immunol 24 (2003) 53-54
15. Shoenfeld Y. The idiotypic network in autoimmunity: Antibodies that bind antibodies that bind antibodies. Nat Med 10 (2004) 17-18
16. Foon K.A., Lutzky J., Baral R.N., Yannelli J.R., Hutchins L., Teitelbaum A., et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18 (2000) 376-384
17. Pride M.W., Shuey S., Grillo-Lopez A., Braslawsky G., Ross M., Legha S.S., et al. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4 (1998) 2363-2370
18. Chong G., Bhatnagar A., Cunningham D., Cosgriff T.M., Harper P.G., Steward W., et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3 H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 17 (2006) 437-442
19. Foon K., John W.J., Chakraborty M., Das R., Teitelbaum A., Garrison J., et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17 (1999) 2889-2895
20. Giaccone G., Debruyne C., Felip E., Chapman P.B., Grant S.C., Millward M., et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organization for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23 (2005) 6854-6864
21. Guthmann M.D., Castro M.A., Cinat G., Venier C., Koliren L., Bitton R.J., et al. Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29 (2006) 215-223
22. Pfisterer J., du Bois A., Sehouli J., Loibl S., Reinartz S., Reuss A., et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 7 (2006) 1568-1577
23. Reinartz S., Köhler S., Schlebusch H., Krista K., Giffels P., Renke K., et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (phase Ib/II). Clin Cancer Res 10 (2004) 1580-1587
24. Sabbatini P., Dupont J., Aghajanian C., Derosa F., Poynor E., Anderson S., et al. Phase I study of abagovomab in patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12 (2006) 5503-5510
25. Wagner U., Köhler S., Reinartz S., Giffels P., Huober J., Renke K., et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment. Clin Cancer Res 7 (2001) 1154-1162
26. +CD25hi regulatory T cells in patients with chronic lymphocytic leukaemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
27. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56 (2006) 641-648
28. Vicari A.P., Luu R., Zhang N., Patel S., Makinen S.R., Hanson D.C., et al. Paclitaxel reduces regulatory T-cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agoniost PF-3512676 in the mouse. Cancer Immunol Immunother 58 (2009) 615-628
29. Garnett C.T., Schlom J., and Hodge J.W. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res 14 (2008) 3536-3544
30. Zhang L., Dermawan K., Jin M., Liu R., Zheng H., Xu L., et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 129 (2008) 219-229
31. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 65 (2005) 1577-1586
32. Svane I.M., Pedersen A.E., Nikolajsen K., and Zocca M.B. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine 26 (2008) 4716-4724
33. Menard C., Ghiringhelli F., Roux S., Chaput N., Mateus C., Grohmann U., et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: Surrogate marker of efficacy of Tremelimumab?. Clin Cancer Res 14 (2008) 5242-5249
34. + T cells following peptide vaccination. J Immunol 176 (2006) 6340-6346